Substituted 1,3-dihydro-imidazol-2-one and 1,3-dihydro-imidazol-2-thione derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
申请人:Bristol Myers Squibb Company
公开号:US07211671B2
公开(公告)日:2007-05-01
The present invention describes novel 1,3-dihydro-imidazol-2-one or 1,3-dihydro-imidazol-2-thione compounds of formula (I):
or a stereoisomer or pharmaceutically acceptable salt or solvate thereof, wherein A, L R1, R2, R3 and R4 are defined in the present specification, which are useful as selective inhibitors of MMP, TACE, aggrecanase or a combination thereof. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.
本发明描述了新的1,3-二氢咪唑-2-酮或1,3-二氢咪唑-2-硫醇化合物,其化学式为(I):或其立体异构体或药学上可接受的盐或溶剂,其中A、L、R1、R2、R3和R4在本说明书中有定义,其作为MMP、TACE、Aggrecanase或其组合的选择性抑制剂具有用途。本发明还涉及包含这些化合物的药物组合物和使用它们的方法。